Minerva Neurosciences to Present at Baird 2014 Health Care Conference

CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, president and chief executive officer of Minerva, will present at the Baird 2014 Health Care Conference on Thursday, September 4, 2014 at 1:25 p.m. EDT in New York City, NY.

A live audio webcast of the presentation will be available online from the investor relations section of the company’s website at http://ir.minervaneurosciences.com. A replay of the presentation will be posted on the Minerva website approximately one hour after the event and will be available for 30 days following the presentation.

About Minerva

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva’s common stock is listed on the NASDAQ Global Market where it trades under the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com/.

CONTACT: Media Contact:

         Jen Ringler

         Berry & Company Public Relations

         Tel: 212-253-8881

         jringler@berrypr.com



         Investor Contact:

         Renee Leck

         Stern Investor Relations

         Tel: 212-362-1200

         renee@sternir.com

Source: Minerva Neurosciences, Inc

News Provided by Acquire Media